Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CEND-1 plus chemotherapy as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma
CTR20240466Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of certepetide in pancreatic adenocarcinoma (PDAC), sponsored by Qilu Pharmaceutical. Started Mar 2024; status: active.
02
Drugs
certepetide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20240466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240466.